slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 230,011-230,040
Pages 10,126
Rows per page 30
Component
230,011-230,040 of 303,780
02
Hyzon | Investor Conference Presentation Deck | 20 slidesHyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Humble Origins1 hit
03
The slide uses a hub-and-spoke diagram where a central image of a fuel cell stack connects to five distinct strategic pillars.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Humble Origins1 hit
07
Uses a vertical timeline-style list to organize four key business pillars.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Early Struggles1 hit
11
The slide uses a dual-section layout: a top table for the ramp-up model and a bottom section for current pipeline status with customer logos.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Rising Success1 hit
13
The chart uses a concentric semi-circle design to represent market layers, with a specific focus on HD trucking as the core.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Rising Success1 hit
15
The slide uses a hub-and-spoke diagram with a central image of a fuel cell stack.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · The Breakthrough1 hit
16
Hyzon | Investor Conference Presentation Deck | 20 slidesHyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · The Breakthrough1 hit
18
The table provides a breakdown of adjustments including fair value changes, stock-based compensation, and one-time charges.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · The Breakthrough1 hit
19
Includes footnotes regarding SEC settlement payments and cash position dates.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · The Breakthrough1 hit
20
The slide uses a before-after donut chart comparison and a supporting table to detail the share movement.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
01
Includes company logo, tagline, mission statement, date, and ticker symbol.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Situation & Context1 hit
02
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Situation & Context1 hit
04
The slide uses a grid-based layout to categorize team members into three distinct groups: Leadership, Board of Directors, and Scientific Advisory Board.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Situation & Context1 hit
05
Immix Biopharma | Investor Presentation Deck | 64 slidesImmix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Situation & Context1 hit
07
The slide uses a hub-and-spoke diagram to centralize the problem of neurotoxicity.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
11
Includes citations from Nature Signal Transduction and Targeted Therapy and Nature Medicine.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
12
The slide uses a combination of bar charts for preclinical data and a summary table for clinical outcomes to demonstrate the superiority of NXC-201.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
13
The slide highlights the structural advantage of the HSL configuration using a (GGGGS)5 linker.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
14
The diagram highlights four key clinical outcomes: no Parkinson's-like symptoms, short hospital stays, broad hospital access, and no deaths in clinical trials.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
16
The slide uses a biological illustration to highlight structural differences in binding domains and intracellular signaling components.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
18
The chart illustrates the pharmacokinetics of the NXC-201 (HBI0101) therapy, highlighting a 30-day clearance window.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
20
The diagram shows a summation of ~29,712 (prevalence) and ~3,040 (derived from incidence) to reach ~32,752 eligible patients.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
21
The slide contrasts existing multi-drug combination therapies with the proposed monotherapy NXC-201.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
22
The slide uses a grouped bar chart to compare hematologic response and cardiac response (NT-proBNP reduction) across four treatment categories.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
23
The slide uses a visual timeline/chart hybrid to compare CAR-T cell expansion, sBCMA reduction, and side effect durations (CRS and ICANS) across three products.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
24
The slide uses a table structure to contrast treatment landscapes and patient outcomes, with a bar chart at the bottom illustrating patient growth.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
25
The slide uses a visual bridge to highlight a 67% improvement in response rates for NXC-201 compared to the average of the three competitors shown.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
27
The slide uses a before-and-after visual comparison to illustrate market expansion.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
28
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
29
The slide uses a two-column layout to separate milestones for two distinct drug programs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit